Wegovy (semaglutide): a new weight loss drug for chronic weight management

Obesity is a growing epidemic within the USA. Because weight gain is associated with an increased risk of developing life-threatening comorbidities, such as hypertension or type 2 diabetes, there is great interest in developing non-invasive pharmacotherapeutics to help combat obesity. Glucagon-like...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Gurdeep, Krauthamer, Matthew, Bjalme-Evans, Meghan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/
https://www.ncbi.nlm.nih.gov/pubmed/34706925
http://dx.doi.org/10.1136/jim-2021-001952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717485/
https://www.ncbi.nlm.nih.gov/pubmed/34706925
http://dx.doi.org/10.1136/jim-2021-001952

Ejemplares similares